164 related articles for article (PubMed ID: 31001932)
1. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
[TBL] [Abstract][Full Text] [Related]
2. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
3. The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation.
Lee HJ; Li CF; Ruan D; Powers S; Thompson PA; Frohman MA; Chan CH
Mol Cell; 2016 Sep; 63(6):1021-33. PubMed ID: 27618486
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer.
Lian WJ; Liu G; Liu YJ; Zhao ZW; Yi T; Zhou HY
Oncol Rep; 2013 Jul; 30(1):193-200. PubMed ID: 23674072
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer.
Liang Y; Li Y; Song X; Zhang N; Sang Y; Zhang H; Liu Y; Chen B; Zhao W; Wang L; Guo R; Yu Z; Yang Q
Cancer Biol Ther; 2018 Feb; 19(2):120-131. PubMed ID: 29293402
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA ATB promotes the epithelial-mesenchymal transition by upregulating the miR-200c/Twist1 axe and predicts poor prognosis in breast cancer.
Li RH; Chen M; Liu J; Shao CC; Guo CP; Wei XL; Li YC; Huang WH; Zhang GJ
Cell Death Dis; 2018 Dec; 9(12):1171. PubMed ID: 30518916
[TBL] [Abstract][Full Text] [Related]
7. YWHAE silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: new insights about YWHAE role in the tumor development and metastasis process.
Leal MF; Ribeiro HF; Rey JA; Pinto GR; Smith MC; Moreira-Nunes CA; Assumpção PP; Lamarão LM; Calcagno DQ; Montenegro RC; Burbano RR
Oncotarget; 2016 Dec; 7(51):85393-85410. PubMed ID: 27863420
[TBL] [Abstract][Full Text] [Related]
8. Expression and significance of Twist, estrogen receptor, and E-cadherin in human breast cancer cells and tissues.
Tan R; Wang L; Song J; Li J; He T
J Cancer Res Ther; 2017; 13(4):707-714. PubMed ID: 28901319
[TBL] [Abstract][Full Text] [Related]
9. SPZ1 is critical for chemoresistance and aggressiveness in drug-resistant breast cancer cells.
Liu X; Han X; Wan X; He C; Wang Y; Mao A; Yu F; Zhou T; Feng L; Zhang P; Jin J; Ma X
Biochem Pharmacol; 2018 Oct; 156():43-51. PubMed ID: 30076850
[TBL] [Abstract][Full Text] [Related]
10. Thymoquinone Enhances Paclitaxel Anti-Breast Cancer Activity via Inhibiting Tumor-Associated Stem Cells Despite Apparent Mathematical Antagonism.
Bashmail HA; Alamoudi AA; Noorwali A; Hegazy GA; Ajabnoor GM; Al-Abd AM
Molecules; 2020 Jan; 25(2):. PubMed ID: 31968657
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
12. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.
Cheng GZ; Chan J; Wang Q; Zhang W; Sun CD; Wang LH
Cancer Res; 2007 Mar; 67(5):1979-87. PubMed ID: 17332325
[TBL] [Abstract][Full Text] [Related]
13. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
14. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
16. TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway.
Zhao D; Qiao J; He H; Song J; Zhao S; Yu J
Mol Med; 2020 Apr; 26(1):27. PubMed ID: 32248791
[TBL] [Abstract][Full Text] [Related]
17. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
[TBL] [Abstract][Full Text] [Related]
18. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
20. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.
Minemura H; Takagi K; Sato A; Takahashi H; Miki Y; Shibahara Y; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2016 Dec; 107(12):1898-1908. PubMed ID: 27627783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
